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ester formation in neonatal lung, with transient
increases in retinoid homeostatic gene expression
Lili Wu1, Reza Zolfaghari1 and A Catharine Ross1,2*Abstract
Background: Mixing a small proportion, 10%, of retinoic acid (RA) into an oral dose of vitamin A (VA) has been
shown to markedly increase retinol uptake and retinyl ester (RE) formation in the neonatal lung, as compared to
VA given alone. Concomitantly, several retinoid homeostatic genes, lecithin:retinol acyltransferase (LRAT), RA-4-
hydroxylase (CYP26B1), and stimulated by retinoic acid gene-6 (STRA6) were upregulated. However, whether
multiple doses may act accumulatively and whether less than 10% RA can be used has not been determined.
Methods: Neonatal rats were treated once on postnatal day (PD) 4 or PD14 with VA alone or VA combined with
10% RA (VARA10%) or a stable analog, Am580 (VAAm10%), or they were treated with multiple doses on PD4, 7, 11,
and 14.
Results: RE increased cumulatively with multiple dosing. However, LRAT, CYP26B1 and STRA6 mRNA levels were
similar for single and multiple treatments, indicating a transient noncumulative impact on gene expression. Lung RE
was elevated with as little as 0.5% RA (P < 0.05) in a single dosing study. Whereas all concentrations of VARA
elevated lung RE in single dosing studies, only 10% RA increased lung RE after multiple dosing, suggesting an
attenuation of RA action with repeated dosing. In contrast, VAAm10%, 2%, and 1% all significantly increased lung
RE after multiple doses (P < 0.05), while also increasing the expression of LRAT and CYP26B1.
Conclusions: These results indicate that the neonatal lung is very sensitive to acidic retinoid exposure and suggest
that a VA combined with a very small fraction of acidic retinoid could be effective in increasing the lung’s storage
pool of VA.
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Retinoids have been implicated in lung development
through promotion of alveolar septation, angiogenesis,
and surfactant synthesis [1]. Before birth, the fetus is ex-
clusively dependent on the maternal supply of VA. Pre-
mature infants, often with very low body weight, are at
increased risk for vitamin A (VA) deficiency, probably
due to a shortened period of transplacental VA supply
before birth [2-5]. This population often also has a high
risk for development of various pulmonary diseases
[6,7]. Animal and human studies have shown that VA* Correspondence: acr6@psu.edu
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stated.supplementation of lactating mothers can improve the
VA status of their postnatal offspring [8-10]. Direct
treatment of the offspring by oral VA supplementation
also increases lung retinyl ester (RE) levels [11,12]. In
several clinical trials, direct VA supplementation to new-
borns modestly improved VA status and reduced risk of
lung injury and dysfunction [13-18]. Additionally, re-
tinoic acid (RA), the active metabolite of VA, has also
shown promising effects in lung repair by regulating
genes involved in lung functioning, cell proliferation,
differentiation, cell-cell communication, and cell-matrix
interactions [19]. It seems likely that the effects of VA
on lung development, differentiation and maintenance
are the result of RA-induced regulation of many genes
related to lung development, including those involved. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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certain growth factors [20]. RA has been shown to in-
crease the level of elastin mRNA in lung fibroblasts [21],
and treatment of neonatal rats with RA resulted in a par-
tial recovery of the septation process and increased forma-
tion of alveoli, even under conditions of stress [22,23].
Previously, we have reported that by combining a por-
tion of acidic retinoid into the VA supplement, referred to
as VARA, the uptake of an oral supplement of retinol and
the formation of RE in the lung were enhanced approxi-
mately 5-fold as compared to the effect of VA supplemen-
tation alone [11,24], concomitant with upregulation of the
levels of transcripts of retinoid homeostatic genes, includ-
ing lecithin:retinol acyltransferase (LRAT) and Stimulated
by RA-6 (STRA6) in short term (6 h) experiments [12].
Thus, we concluded that the redirection of VA flow into
the lung by the VARA treatment, compared with VA
alone, could be a result of the rapid upregulation of LRAT
and STRA6 genes. Other investigators have demonstrated
that LRAT and STRA6 cooperate in mediating retinol up-
take and storage, for when both genes were co-expressed
in retinal pigment epithelial cells the uptake and esterifica-
tion of retinol exceeded that in cells expressing either one
of these genes alone [25].
Our previous studies in neonatal rats or mice tested
only VARA with 10 mol% of RA, referred to herein as
VARA10%, which increased the content of lung RE in-
creased ~5-fold more as compared to same amount of VA
alone [11,24], and VA combined with Am580 (VAAm10%),
a C-4 methyl substituted analog of all-trans-RA that is re-
sistant to rapid catabolism by enzymes of the cytochrome
P450 CYP26 family. LRAT and STRA6 mRNA levels were
increased even more strongly as compared to VARA10%;
moreover, Am580 also induced a more persistent rise
in the retinoid catabolic genes, CYP26B1 in lung and
CYP26A1 in liver [11,12]. However, our previous studies
did not test VARA prepared with lower amounts of RA.
Because minimizing unnecessary exposure to VA or RA
may be an important consideration for translation of ro-
dent studies into clinical trials, it is important to better
understand the effects of dosing and acidic retinoid con-
tent on lung RE formation and retinoid homeostatic genes.
Therefore the present studies were designed to answer the
following questions: Do multiple treatments of VA com-
bined with 10% acidic retinoid increase RE in the neonatal
lung in an accumulative manner? Are VARA or VAAm
prepared with a lower proportion of RA or Am580 still ef-
fective in promoting RE storage in the neonatal lung?
Materials and methods
Materials and dose preparation
VA in the form of all-trans-retinyl palmitate and all-
trans-RA were purchased from Sigma-Aldrich (St. Louis,
MO). Am580 was from by H. Kagechika, University ofTokyo. Either RA or Am580 was admixed with VA at a
molar ratio of 10 VA to 1 RA or Am580, in canola oil (see
[11,12] for rationale); oil was also used as a placebo con-
trol for oral dosing. In designated experiments the propor-
tion of RA or Am580 was modified; each dose of VARA
or VAAm delivered the same amount of VA but RA or
Am580 was admixed at 10%, 5%, 2%, or 1% (VARA and
VAAm), or 0.5% (VARA only), relative to VA.
Animals and experimental designs
Animal procedures were approved by the Institutional
Animal Use and Care Committee of The Pennsylvania
State University. We conducted several experiments to
investigate the effects of dosing schedule: 1) single early
dosing on PD4; 2) single later dosing on PD14, and 3) mul-
tiple dosing throughout the period of lung septation (one
dose given daily on PD4, 7, 11, and 14). Neonatal rats were
randomly divided into 6 groups (n = 4-6/group) that re-
ceived: oil (control), VA alone, RA alone, Am580 alone, VA
combined with RA (VARA), or VA combined with Am580
(VAAm). Other studies tested the effect different levels of
RA or Am580 in the VARA or VAAm dose, using either
single or multiple dosing schedules as above. The number
of animals per treatment is given in the legends to figures.
In all studies, neonatal pups were delivered by Sprague-
Dawley dams fed a nutritionally complete VA adequate diet
(AIN-93G) [26] containing 4 μg retinol/g. Since the pups in
each study were obtained from several litters, the sexes
were distributed evenly among the groups and the average
body weight of each group was similar. Before dosing pups
were weighed and the dose volume was adjusted to 0.4 μL/g
body weight. This procedure delivered 6 mg/kg VA, which
was kept constant, and the designated proportion of ad-
mixed RA or Am580. Pups were killed with prolonged
carbon dioxide inhalation and exanguination 6 h after the
single dose or 6 h after the final dose in the multiple dos-
ing experiments. The lungs were removed, trimmed and
weighed. All samples were frozen in liquid nitrogen imme-
diately and then stored at -80°C for later analysis.
Retinoid analysis
Tissues were analyzed for total retinol after saponification.
Extraction, saponification, and HPLC analysis were con-
ducted as previously described [11]. In lung tissue, >90%
of total retinol is esterified [11] and thus total retinol rep-
resent RE in our studies. Retinal was not detected.
Gene mRNA determination
Total RNA from lung tissues of individual pups was ex-
tracted using Trizol (Invitrogen, Carlsbad, CA) and then re-
verse transcribed using Moloney murine leukemia virus
reverse transcriptase (Promega, Madison, WI). The diluted
reaction product (1/20) was used for real-time PCR (rt-


















































































































Figure 1 Lung RE concentration after a single treatment or
multiple treatments with VA alone, all-trans-retinoic acid (RA)
alone, or combination of VA and 10% RA (VARA), Am580 alone,
and combination of VA and 10% Am580 (VAAm). Neonatal rats were
treated with a single dose, prepared and delivered as in Experimental
Methods, which was given either early during the period of lung
septation (PD4) (A), or near the end of the period of lung septation
(PD14) (B), or as multiple doses on PD 4, 7, 11, and 14 (C). Lung total
retinol concentration, which is mainly RE (see Materials and methods),
was determined on tissue collected 6 h after the single dose or final
treatment in the multiple dosing design. Data are presented as means ±
SEM. Each treatment group included n= 4-6 neonates. Statistical analysis
was conducted on log10-transformed data using one-factor ANOVA and
Fisher’s Least Significant Difference posthoc test. Groups with different
letters differed significantly, P < 0.05. Asterisks in panel C mark
significant differences between the PD14 single dosing study (B) and
multiple dosing study (C), tested for each treatment by unpaired t-test.
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The PCR cycling program was first set at 94°C for 3 min
to activate the Taq polymerase and then at 40 cycles of
94°C for 20 s, 60°C for 30 s, 72°C for 30 s and 75°C for
1 sec using the DNA Engine2 Opticon with Continuous
Florescence Detector (BioRad). The primers used to
detect specific RNAs were: for rat LRAT (AF255060),
5′- CGGACCCATTTTACCCACTA-3′ (forward) and 5′-
CAGACTGCAGGAAGGGTCAT-3′ (reverse); for rat
CYP26B1 (NM_181087), 5′-TTGAGGGCTTGGAGTTGG
T-3′ (forward) and 5′-AACGTTGCCATACTTCTCGC-3′
(reverse); for rat STRA6 (NM_0010029924), 5′-CCGATCC
TGGACAGTTCCTA -3′ (forward) and 5′-CCACCTGG
TAAGTGGCTGTT -3′ (reverse), for rat 18S ribosomal
RNA (FQ225624), 5′- CGCGGTTCTATTTTGTTGGT-3′
(forward) and 5′- AGTCGGCATCGTTTATGGTC-3′ (for-
ward). The mRNA expression level of each sample was
corrected by calculating mRNA-to-ribosomal 18S RNA ra-
tio. Data were normalized to the average value for the con-
trol group, set at 1.0, prior to statistical analysis.
Statistical analysis
Data are shown as the means ± SEM. Differences between
groups were tested by one-factor ANOVA followed by
Fisher’s least significant difference test, using GraphPad
Prism (San Diego, CA). For comparisons of mRNAs, the
mean value of the control group was set to a value of 1.0,
and the mean values for the other groups were converted
accordingly prior to statistical testing. If group variances
were unequal, the individual values were transformed to
log10 values before statistical analysis. Differences with
P < 0.05 were considered statistically significant.
Results
Multiple dosing resulted in a higher, accumulative
increase in lung RE contents
Three experiments were conducted in which the timing of
the dosing differed between PD4 and PD14, considered the
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ments were given once either on PD4 or PD14, or as re-
peated doses on PD4, 7, 11, and 14, with tissue collection
6 h after the single dose or final dose in the repeated dosing
study. In each of these studies the treatments included oil
(control), VA alone, RA alone (matched to the amount in
VARA10%), VARA10%, Am580 alone (matched to the
amount in VAAm10%), and VAAm10%. After single dosing
on PD4 (Figure 1A), treatments with VARA10% and
VAAm10% increased lung RE levels more than VA alone,
which itself increased lung RE 2-fold above the control
value (P < 0.05). These results agree with those of our previ-
ous observations that VARA and VAAm580 containing
10% of acidic retinoid synergistically increased lung RE con-
tent as early as 6 h after dosing in young rat pups [11,12].
After single dosing on PD14 (Figure 1B), a similar pattern
was observed among the treatments, which suggests a con-
sistent mechanism of response to VARA throughout the
period of lung septation. When each treatment was com-
pared between the two ages, lung RE was significantly
greater on PD14 than PD4 (all P < 0.05 except for P = 0.056
between VA groups on PD4 versus PD14); therefore older
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Figure 2 Expression levels of LRAT, and CYP26B1 and STRA6 mRNA aft
retinoids. Neonatal rats received an early single dose on PD4 (A-C), or multip
Quantitative PCR results were normalized to ribosomal 18S RNA and the avera
are presented as means ± SEM. Each treatment group included n = 4-6 neona
one-factor ANOVA and Fisher’s Least Significant Difference posthoc test. Grouconcentration and they responded slightly more robustly to
treatment. In a third experiment, we tested multiple dosing
with VARA10% and VAAm10%, given on PD4, 7, 11, and
14. Multiple dosing increased lung RE (Figure 1C) more
than single dosing on PD14 (all P < 0.05 versus single-dose
on PD14). However, for VA and RA given alone, there was
no additive increase. Notably, repeated treatment with
Am580 alone increased lung RE in a cumulative manner,
both as compared to the control group, the VA group, and
the group treated with a single dose of Am580 (all P < 0.05,
Figure 1C). This suggests that Am580, as a stable analog of
RA, redirected endogenous retinol that was present in the
absence of VA supplementation into the lung.
Multiple treatments of VARA had no cumulative effect on
the expression of lung homeostatic genes, but VAAm
prolonged gene expression
Next we examined single dosing versus multiple dosing
with VA, RA, VARA, and VAAm on the expression of ret-
inoid homeostatic genes. After single dosing on PD4, LRAT
mRNA was significantly increased in all groups that
had received a treatment containing an acidic retinoid:
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er treatments with single (PD4) and multiple doses of VA and acidic
le doses on PD4, 7, 11, and 14 (D-F), as described for Figure 1A and C.
ge value for the control group was set to 1.0 for each experiment. Data
tes. Statistical analysis was conducted on log10-transformed data using
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Figure 3 Lung RE concentration after a single treatment with
VA alone, or VARA or VAAm prepared with different
percentages of acidic retinoid. In A, neonatal rats were treated
on PD4-5 with a single dose and tissue was collected 6 h later (A).
In B, neonatal rats were treated with multiple doses on PD4, 7, 11,
and 14 and lung tissue was collected 6 h after the last dose. Data
are presented as means ± SEM. Statistical analysis was conducted on
log10-transformed data using one-factor ANOVA and Fisher’s Least
Significant Difference posthoc test. Groups with different letters
differed significantly, P < 0.05.
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increase was significant only for VARA, Am580, and
VAAm (Figure 2B). STRA6 mRNA increased to a lesser
extent and was more variable and therefore was not sig-
nificantly regulated by these treatments (Figure 2C). Re-
sults for single dosing on PD14 (data not shown) were
similar to those for PD4. In the multiple-dosing study,
VARA significantly increased the level of LRAT (Figure 2D)
but not CYP26B1 (Figure 2E) mRNA (P < 0.05), while both
Am580 and VAAm dramatically increased LRAT and
CYP26B1 mRNAs. For STRA6, results on PD14 (Figure 2F)
were similar to those on PD4. Since all of these mea-
surements were made 6 h after the single dose or the
last dose in the multiple dosing protocol, the results
thus suggest that RA, probably due to its very short
half-life or due to its induction of CYP26B1, produced
only a transient stimulation of the expression of these
retinoid-homeostatic genes, while, in contrast, the stable
retinoid analog Am580 induced a sustained elevation of
LRAT and CYP26B1 gene expression.
Previously, the lowest concentration of RA or Am580
admixed with VA that may enhance lung RE formation
has not been determined. Therefore we next conducted
a single-dosing experiment in which neonatal rats were
treated at early neonatal age (PD4-5) with oil, VA alone,
or dilutions of VARA with RA at 10%, 5%, 2%, 1% or
0.5% relative to VA. Figure 3A shows that lung RE in-
creased after treatments with VARA10%, 5%, 2% and 1%,
while VARA0.5% produced less of an increase, although
still above that with VA alone (all P < 0.05 versus VA).
We then investigated multiple doses of VARA at dilu-
tions of 10%, 2% and 1% RA and of VAAm at 10%, 2% and
1% Am580, each in comparison to control and VA treated
pups. In this study, all doses that had been used in the sin-
gle dose study (shown in Figure 1), produced a greater
increase in lung RE after multiple dosing (Figure 3B),
which is consistent with the cumulative effect of multiple
doses shown above for VARA10%. However, VARA2%
and VARA1% did not produce an increase greater than
VA alone after multiple dosing. This may suggest an at-
tenuation of the effect of RA at lower doses, due to rapid
catabolism. Consistent with this notion, multiple dosing
using VA combined with the stable retinoid Am580, from
VAAm10%, to VAAm1%, all resulted in increased lung
RE, in some cases exceeding 100 nmol/g.
Retinoid-regulated gene expression with diluted doses of
VARA and VAAm
Based on these results we hypothesized that an upregula-
tion of retinol uptake and esterification might be transient
in the lung of pups treated with more diluted forms
of VARA, due to rapid catabolism of the more limited
amount of RA, whereas the effect of Am580 would be
more persistent and thus we hypothesized that VAAmprepared with a lower proportion of Am580 would still be
effective. Thus, we compared STRA6, LRAT, and CYP26B1
expression in neonatal lung using samples collected 6 h
after the final dose of a study with multiple-dose treat-
ments of either VARA at 10%, 2% and 1% of RA, or
VAAm at 10%, 2% and 1% of Am580, or VA alone (as in
Figure 3B). For each of these genes, the expression level
after multiple treatments with VARA 10%, 2% or 1% did
not differ from treatment with VA alone, while VA alone
elevated expression slightly but significantly compared
to the placebo-treated control group (Figure 4). By con-
trast, treatment with VAAm10%, 2% or 1% all significant

































































































































































Figure 4 Expression levels of STRA6, LRAT, and CYP26B1 mRNA
after multiple doses of VA and VA combined with different
mole percentages of acidic retinoids. Neonatal rats were treated
with on muliple doses on PD4, 7, 11, and 14. An equal amount of
VA, equivalent to 6 mg retinol/kg was given either alone or
combined with varying proportions of RA or Am580, from 10% to
1% compared to VA. Gene expression levels were determined for
STRA6 (A), LRAT (B), and CYP26B1 (C) 6 h after the final dose.
Quantitative PCR results were normalized to ribosomal 18S RNA and
the average value for the control group was set to 1.0 for each
experiment. Data are presented as means ± EM with values for
individual neonates shown as symbols. Statistical analysis was
conducted on log10-transformed data using one-factor ANOVA
and Fisher’s Least Significant Difference posthoc test. Groups with
different letters differed significantly, P < 0.05.
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to VA alone. The relative increases for LRAT and
CYP26B1 were greater than those for STRA6 and ex-
hibited a dose-response trend.
Discussion
VA is essential in lung development and thus it is pos-
sible that supplementation with VARA during early post-
natal life could be advantageous in neonates at risk of
low VA status as a means of providing an adequate
supply of VA to lung tissue for the production of en-
dogenous retinoids. Previously, we reported that VARA,
compared to VA alone, increased lung RE about 5 times
more [12]. Biesalski [27] has referred to this synergy of
VA and RA as “metabolic priming”, and we believe this
is an apt description of how the RA component of the
VARA preparation is working to augment VA uptake
and storage in the lung. Previous studies showed that
VARA was effective in increasing lung RE even in the
face of inflammation [28], and VARA also has improved
outcome, as suggested by reduced markers of inflamma-
tion and improved morphology in a model of hyperoxic
lung injury in the neonatal mouse [29,30].
Previous studies had not tested whether repeated
treatments (multiple dosing) during the neonatal period
would have an additive effect on either RE formation or
the level of gene expression, or whether the amount of
acidic retinoid could be reduced below 10%, relative to
VA, and still promote RE formation. The ability to de-
liver a lower percentage of RA or Am580, if effective in
increasing lung RE, is important to test as, if effective, it
would allow for a reduced total exposure to these com-
pounds during early postnatal development. Our present
experiments show, firstly, that single treatments on PD4
compared to PD14 resulted in very similar responses
(Figure 1A and 1B), suggesting that the lung remains re-
sponsive to VARA at times near both the beginning and
the end of the septation period. Secondly, multiple treat-
ments increased lung RE contents in a manner that was
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mulative in quantity (Figure 1C vs. A and B). The cumu-
lative increase is of interest because it suggests that
intermittent, periodic dosing is sufficient to maintain an
elevated level of RE in lung tissue over a period of time,
especially if the acidic retinoid is persistent, and may
suggest that lower doses would be effective in maintain-
ing a moderate increase in lung RE over time. Thirdly,
VARA and VAAm, each composed with 10% of acidic
retinoid, did not differ from each other with respect to
lung RE formation after a single dose, but VAAm
produced a stronger effect than VARA after multiple
dosing (Figure 1C), probably due to the longer half-life
of Am580 compared to RA. Indeed, with VAAm, it
appears the total dose of both retinoids combined can
be reduced by half or more and still have an equivalent
effect as VARA10% (Figure 3). The finding that treat-
ment with Am580 alone, in the absence of supplementa-
tion with VA, significantly increased lung RE (Figure 1C)
indicates the power of Am580 to redirect endogenous
VA, presumably derived from liver or other storage tis-
sues, into the lung. Fourthly, the results of gene expres-
sion analysis provide a possible explanation for the
difference between VARA and VAAm treatments, in that
treatments containing Am580 increased LRAT expres-
sion substantially, in both the single dose and multiple
dosing experiments (Figure 2). The persistence of LRAT
gene expression even 24 h after the final dose in the
multiple-dosing study may have led to an exaggerated
formation of lung RE.
The results of our dose-dilution studies with a fixed
amount of VA combined with different amounts of RA
and Am580 showed that small amounts of acidic retin-
oid significantly increased lung RE accumulation. The
lowest effective concentration of RA was 0.5% in PD 4-5
neonates after a single dose (Figure 3A). Interestingly, in
older PD14 neonates after multiple doses (Figure 3B),
only VARA10% significantly elevated lung RE, compared
either to VA alone, VARA2%, or VARA1%. In our previ-
ous 12 h experiments [12], we suggested that the activity
of RA is only transient, consistent with a high turnover
rate of RA in vivo [31], due to transient upregulation
of retinoid homeostatic genes. We speculate that the
loss of synergy observed with VARA2% and 1% in our
multiple-dosing study (Figure 3B) could be due to a
more rapid elimination of the small amount of RA
in the VARA dose. This idea was supported by our
multiple-dosing experiment using the more stable ana-
logue of RA, Am580 (Figure 1C), in which VAAm1%
increased lung RE formation compared to VA alone
(Figure 3B).
Although the up-regulation of STRA6 in these studies
was modest as compared to that of LRAT and CYP26 in
response to either VARA or VAAM doses, it was stillstatistically significant (Figure 4A). The essentiality of
STRA6 for retinol uptake from plasma RBP, except in
the eye, has been questioned recently based on studies
in STRA6 knock-out mice [32], but STRA6 might still
participate in the enhanced uptake of retinol under con-
ditions when the gene is expressed and responsive to
acidic retinoids, as in lung of wildtype neonates. Studies
in LRAT knock-out mice have demonstrated its import-
ance in retinol uptake, including in adult tissues, includ-
ing lung [33]. The ability of RA to upregulate these
genes, even transiently, could be applied in therapies for
neonates, in which VA stores are low at birth, to rapidly
increase the tissue’s content of VA, which may improve
the in situ formation of bioactive retinoids. Having an
adequate supply of RE in lung tissue may be critical for
adequate formation of bioactive retinoids. An acute ac-
cumulation and utilization of RE has been shown during
the alveolar stage of lung development [34,35], when,
concurrently, retinol and RA increased in lung fibro-
blasts, suggesting an increased demand for retinoids in
normal postnatal lung development [36].
In summary, these studies have provided evidence that
multiple dosing with VARA or VAAm can rapidly and
markedly elevate lung RE contents in neonatal rats, and
that the magnitude of increase can be controlled by the
type and amount of acidic retinoid admixed with VA and
the frequency of dosing. A small amount of RA admixed
with VA may be a useful approach to increasing the de-
livery of retinol to the lungs. Our findings thus provide
some clues for a more efficient and possibly better thera-
peutic strategy that may improve lung RE formation in
neonatal lungs.
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